Fryad Majeed RAHMAN

Post-doctorate Researcher

Molecular Immuno Virology

C2VN (AMU, INSERM 1263, INRA 1062) laboratory

Faculty of Medicine, Aix-Marseille University - FRANCE

PhD in Human Molecular Genetics

NORT, UMR Inserm U1062, INRA 1260

Faculty of Medicine - Timone Campus

University of Aix-Marseille - FRANCE

MSc in Genomics and Health

EA 4263, Therapy of Genetic Disorders

Faculty of Medicine - Timone Campus

University of the Mediterranean - FRANCE

MSc in Biotechnology

Department of Biology / Faculty of Science University of Babylon - IRAQ

BSc in Biology - Microbiology

Department of Biology / Faculty of Science University of Salahaddin - Kurdistan / IRAQ

Publications: (13) Scientific Articles, and (1) Book Chapter.

and (3) Conf. papers.

e-mail: fryad.rahman@univsul.edu.iq

Mobile: +964 (0) 770 137 6713

Area of My Research

The Formyl Peptide Receptor 2 (FPR2) is a novel promising target for the treatment of influenza. During viral infection, FPR2 is activated by annexinA1, which is present in the envelope of influenza viruses; this activation promotes virus replication. Here, we investigated whether blockage of FPR2 would affect the genome trafficking of influenza virus. We found that, upon infection and cell treatment with the specific FPR2 antagonist WRW4 or the anti-FPR2 monoclonal antibody, FN-1D6-AI, influenza viruses were blocked into endosomes. This effect was independent on the strain and was observed for H1N1 and H3N2 viruses. In addition, blocking FPR2signaling in alveolar lung A549 epithelial cells with the monoclonal anti-FPR2 antibody significantly inhibited virus replication. Altogether, these results show that FPR2signaling interferes with the endosomal trafficking of influenza viruses and provides, for the first time, the proof of concept that monoclonal antibodies directed against FPR2 inhibit virus replication. Antibodies-based therapeutics have emerged as attractive reagents in infectious diseases. Thus, this study suggests that the use of anti-FPR2 antibodies against influenza hold great promise for the future.